We previously demonstrated increased ncBAF abundance and activity in other cBAF-mutated cancer contexts including SMARCB1- and SMARCE1-deficient cancers.18,45 Here, our work demonstrates the intriguing persistence of both ncBAF and PBAF function in the absence of cBAF, a therapeutic vulnerability that we validate both genetically and pharmacologically. Here, SMARCB1 is linked to cancer.